| Autor: |
Janusek, Marissa, Geswein, Laura, DiGrazia, Lisa, Schultz, Kathryn, Crank, Christopher W., Fung, Henry C. |
| Předmět: |
|
| Zdroj: |
Journal of Hematology Oncology Pharmacy; Mar2016, Vol. 6 Issue 1, p12-16, 5p |
| Abstrakt: |
Background: High doses of chemotherapy in patients who undergo autologous hematopoietic stem-cell transplantation (HSCT) can result in delayed or incomplete engraftment. Granulocyte colony-stimulating factors are used to decrease the time to engraftment; however, the optimal timing of filgrastim initiation following autologous HSCT is unknown. Objective: This retrospective study at a single institution compared neutropenia recovery of patients who received filgrastim on day +5 after autologous HSCT versus those who received it on day +10. Methods: Patients were included if they began receiving filgrastim on day +5 (±1) or day +10 (±1) after autologous HSCT. Patients were matched based on age and type of malignancy. The primary end point was time to engraftment. Secondary end points included length of hospital stay, rates of infection, and total febrile days. Results: Data were collected for 158 patients. Time to engraftment was faster in patients who began receiving filgrastim on day +5 than in patients who began receiving filgrastim on day 5 +10 (8.27 days vs 8.96 days; P = .006). The average number of doses per patient differed significantly: 7 for day +5 recipients and 3 for day +10 recipients (P <.01). No significant differences were observed in the length of hospital stay, rates of infection, or total febrile days. Conclusion: The authors believe that the difference in engraftment time between the study groups is not clinically meaningful, because secondary end points were similar in these groups. Results indicate that initiating filgrastim on day +10 following autologous HSCT would be safe and economical. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
